Management of traditional risk factors for the development and progression of chronic kidney disease
R Lo, Y Narasaki, S Lei, CM Rhee - Clinical Kidney Journal, 2023 - academic.oup.com
Chronic kidney disease (CKD) and its downstream complications (ie cardiovascular) are a
major source of morbidity worldwide. Additionally, deaths due to CKD or CKD-attributable …
major source of morbidity worldwide. Additionally, deaths due to CKD or CKD-attributable …
Effects of PCSK9 on thrombosis and haemostasis in a variety of metabolic states: Lipids and beyond
S Chong, G Mu, X Cen, Q Xiang… - … Journal of Molecular …, 2024 - spandidos-publications.com
Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors are widely recognised as
being able to induce a potent reduction in low‑density lipoprotein‑cholesterol. An increasing …
being able to induce a potent reduction in low‑density lipoprotein‑cholesterol. An increasing …
[HTML][HTML] Preclinical toxicity assessment of a peptide-based antiPCSK9 vaccine in healthy mice
AA Momtazi-Borojeni, M Banach, SA Tabatabaei… - Biomedicine & …, 2023 - Elsevier
Background Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition is a novel
cholesterol-lowering treatment for decreasing the risk of atherosclerosis. We have previously …
cholesterol-lowering treatment for decreasing the risk of atherosclerosis. We have previously …
Sex and statin-related genetic associations at the PCSK9 gene locus: results of genome-wide association meta-analysis
Background Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key player of lipid
metabolism with higher plasma levels in women throughout their life. Statin treatment affects …
metabolism with higher plasma levels in women throughout their life. Statin treatment affects …
[HTML][HTML] Meta-GWAS on PCSK9 concentrations reveals associations of novel loci outside the PCSK9 locus in white populations
A Kheirkhah, JF Schachtl-Riess, C Lamina, S Di Maio… - Atherosclerosis, 2023 - Elsevier
Background and aims Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key
regulator of lipid homeostasis. A few earlier genome-wide association studies (GWAS) …
regulator of lipid homeostasis. A few earlier genome-wide association studies (GWAS) …
Association of Serum Afamin Concentrations With Kidney Failure in Patients With CKD: Findings From the German CKD Cohort Study
B Kollerits, F Kotsis, MP Schneider… - American Journal of …, 2024 - Elsevier
Abstract Rationale & Objective Afamin is a vitamin E-binding glycoprotein primarily
expressed in liver and kidney. This study investigated whether serum afamin concentrations …
expressed in liver and kidney. This study investigated whether serum afamin concentrations …
Immune-Related Genes and Immune Cell Infiltration Characterize the Maturation Status of Arteriovenous Fistulas: An Integrative Bioinformatics Study and …
P Lu, T Wang, Z Wan, M Wang, Y Zhou… - Journal of …, 2024 - Taylor & Francis
Purpose Arteriovenous fistula (AVF) is the preferred vascular access for hemodialysis, but
the low maturation rate is concerning. Immune cells' impact on AVF maturation lacks …
the low maturation rate is concerning. Immune cells' impact on AVF maturation lacks …
[HTML][HTML] Proprotein convertase subtilisin/kexin type 9 (PCSK9) as a marker of coronary lesion severity in stable coronary artery disease (CAD) patients
Coronary artery disease (CAD) remains a significant global health concern with
considerable high morbidity and mortality and its development is influenced by various …
considerable high morbidity and mortality and its development is influenced by various …
[HTML][HTML] KLKB1 and CLSTN2 are associated with HDL-mediated cholesterol efflux capacity in a genome-wide association study
JF Schachtl-Riess, S Schönherr, C Lamina, L Forer… - Atherosclerosis, 2023 - Elsevier
Background and aims HDL-mediated cholesterol efflux capacity (CEC) may protect from
cardiovascular disease. Thus, we aimed to identify its genetic and non-genetic determinants …
cardiovascular disease. Thus, we aimed to identify its genetic and non-genetic determinants …
前蛋白转化酶枯草溶菌素9 在肾脏疾病的研究
张志宏， 王金泉 - 肾脏病与透析肾移植杂志, 2022 - njcndt.com
肾脏疾病患者常合并脂质代谢紊乱, 且心脑血管事件风险显著升高. 研究发现,
前蛋白转化酶枯草溶菌素9 (PCSK9) 不仅是肝脏低密度脂蛋白(LDL) 清除的关键调节因子 …
前蛋白转化酶枯草溶菌素9 (PCSK9) 不仅是肝脏低密度脂蛋白(LDL) 清除的关键调节因子 …